| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Philip Gorwoo. Meeting everyday challenges: antipsychotic therapy in the real world. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 16 Suppl 3. 2006-11-14. PMID:16872807. |
studies such as the clinical antipsychotic trials of intervention effectiveness (catie) study, the schizophrenia outpatient health outcomes (soho) study and the broad effectiveness trial with aripiprazole (beta) studies, together with large-scale database analyses, are now producing results supplementary to those observed in long-term, open-label extension studies. |
2006-11-14 |
2023-08-12 |
Not clear |
| Rajiv Tandon, Ronald N Marcus, Elyse G Stock, Linda C Riera, Dusan Kostic, Miranda Pans, Robert D McQuade, Margaretta Nyilas, Taro Iwamoto, David T Crandal. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophrenia research. vol 84. issue 1. 2006-09-08. PMID:16483745. |
a prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: broad effectiveness trial with aripiprazole (beta). |
2006-09-08 |
2023-08-12 |
Not clear |
| Rajiv Tandon, Ronald N Marcus, Elyse G Stock, Linda C Riera, Dusan Kostic, Miranda Pans, Robert D McQuade, Margaretta Nyilas, Taro Iwamoto, David T Crandal. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophrenia research. vol 84. issue 1. 2006-09-08. PMID:16483745. |
beta was designed to evaluate the overall effectiveness of aripiprazole in patients with schizophrenia or schizoaffective disorder treated in a general psychiatry outpatient practice setting. |
2006-09-08 |
2023-08-12 |
Not clear |
| Péter Gaszne. [Clinical observations with aripiprazole in schizophrenia]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology. vol 8. issue 1. 2006-08-24. PMID:16841563. |
[clinical observations with aripiprazole in schizophrenia]. |
2006-08-24 |
2023-08-12 |
Not clear |
| Mathias B Forreste. Aripiprazole exposures reported to Texas poison control centers during 2002-2004. Journal of toxicology and environmental health. Part A. vol 69. issue 18. 2006-08-16. PMID:16864422. |
aripiprazole is an oral atypical antipsychotic drug used in the treatment of schizophrenia and potentially other behavior disorders. |
2006-08-16 |
2023-08-12 |
human |
| G Luebbe, S Kropp, E Harms, M Ziegenbei. Extensive weight loss in a patient with schizophrenia after switching from olanzapine to aripiprazole. A case report. Pharmacopsychiatry. vol 39. issue 2. 2006-08-10. PMID:16555168. |
extensive weight loss in a patient with schizophrenia after switching from olanzapine to aripiprazole. |
2006-08-10 |
2023-08-12 |
Not clear |
| D C Henderson, L Kunkel, D D Nguyen, C P Borba, T B Daley, P M Louie, O Freudenreich, C Cather, A E Evins, D C Gof. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta psychiatrica Scandinavica. vol 113. issue 2. 2006-08-02. PMID:16423166. |
an exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. |
2006-08-02 |
2023-08-12 |
human |
| D C Henderson, L Kunkel, D D Nguyen, C P Borba, T B Daley, P M Louie, O Freudenreich, C Cather, A E Evins, D C Gof. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta psychiatrica Scandinavica. vol 113. issue 2. 2006-08-02. PMID:16423166. |
we conducted this 6-week open-label trial to examine the effects of adjunctive aripiprazole in clozapine-treated subjects on weight, lipid and glucose metabolism, as well as positive and negative symptoms of schizophrenia. |
2006-08-02 |
2023-08-12 |
human |
| A F Christensen, J Poulsen, C T Nielsen, B Bork, A Christensen, M Christense. Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study. Acta psychiatrica Scandinavica. vol 113. issue 2. 2006-08-02. PMID:16423167. |
patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study. |
2006-08-02 |
2023-08-12 |
Not clear |
| A F Christensen, J Poulsen, C T Nielsen, B Bork, A Christensen, M Christense. Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study. Acta psychiatrica Scandinavica. vol 113. issue 2. 2006-08-02. PMID:16423167. |
the purpose was to carry out a naturalistic study on efficacy, safety and tolerability of aripiprazole during treatment of schizophrenia. |
2006-08-02 |
2023-08-12 |
Not clear |
| A F Christensen, J Poulsen, C T Nielsen, B Bork, A Christensen, M Christense. Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study. Acta psychiatrica Scandinavica. vol 113. issue 2. 2006-08-02. PMID:16423167. |
fifty-one patients with an icd-10 diagnosis of schizophrenia and partial responders to prior antipsychotic medication were offered treatment with aripiprazole as monotherapy or in combination their prior medication. |
2006-08-02 |
2023-08-12 |
Not clear |
| Harpeet S Duggal, Dattatreya N Mendheka. High-dose aripiprazole in treatment-resistant schizophrenia. The Journal of clinical psychiatry. vol 67. issue 4. 2006-06-16. PMID:16669736. |
high-dose aripiprazole in treatment-resistant schizophrenia. |
2006-06-16 |
2023-08-12 |
Not clear |
| H G El-Sayeh, C Morgant. Aripiprazole for schizophrenia. The Cochrane database of systematic reviews. issue 2. 2006-06-15. PMID:16625607. |
aripiprazole for schizophrenia. |
2006-06-15 |
2023-08-12 |
Not clear |
| Marius K Nickel, Moritz Muehlbacher, Cerstin Nickel, Christian Kettler, Francisco Pedrosa Gil, Egon Bachler, Wiebke Buschmann, Nadine Rother, Reinhold Fartacek, Christoph Egger, Javaid Anvar, Wolfhardt K Rother, Thomas H Loew, Patrick Kapla. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. The American journal of psychiatry. vol 163. issue 5. 2006-06-12. PMID:16648324. |
aripiprazole is a relatively new atypical antipsychotic agent that has been successfully employed in therapy for schizophrenia and schizoaffective disorders. |
2006-06-12 |
2023-08-12 |
Not clear |
| Warren A Kinghorn, Joseph P McEvo. Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert review of neurotherapeutics. vol 5. issue 3. 2006-06-05. PMID:15938662. |
randomized studies have demonstrated the efficacy of aripiprazole relative to placebo in the treatment of acute relapse of schizophrenia and schizoaffective disorder, maintenance treatment of schizophrenia, and treatment of acute bipolar mania. |
2006-06-05 |
2023-08-12 |
Not clear |
| G Gründer, M Kungel, M Ebrecht, T Göröcs, S Model. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry. vol 39 Suppl 1. 2006-05-24. PMID:16508892. |
aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. |
2006-05-24 |
2023-08-12 |
Not clear |
| J P Lindenmayer, Anzalee Kha. Pharmacological treatment strategies for schizophrenia. Expert review of neurotherapeutics. vol 4. issue 4. 2006-04-20. PMID:15853589. |
the pharmacological choices for the treatment of schizophrenia have been greatly expanded with the availability of the atypical compounds clozapine (clozaril, novartis), risperidone (risperdal, janssen-cilag), olanzapine (zyprexa, eli lilly & co.), quetiapine (seroquel, astrazeneca), ziprasidone (geodon, pfizer inc.) and aripiprazole (abilify, otsuka pharmaceutical co. ltd). |
2006-04-20 |
2023-08-12 |
Not clear |
| Jean Y Zhang, Dianne M Kowal, Stanley P Nawoschik, Zhuangwei Lou, John Dunlo. Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochemical pharmacology. vol 71. issue 4. 2006-03-29. PMID:16336943. |
the modest 5-ht2a antagonism and 5-ht2c partial agonism, along with reported d2 and 5-ht1a partial agonism, may allow aripiprazole to stabilize the disturbed dopamine-serotonin interplay in schizophrenia with a moderate yet adequate pharmacological intervention. |
2006-03-29 |
2023-08-12 |
human |
| Paul J Goodnic. Higher than Physician's Desk Reference (US) doses on atypical antipsychotics. Expert opinion on drug safety. vol 4. issue 4. 2006-02-28. PMID:16011445. |
the others: respectfully, olanzapine (schizophrenia: 15 mg, mania: 20 mg), quetiapine (schizophrenia: 750 mg; mania: 800 mg), ziprasidone (schizophrenia and mania: 160 mg) and aripiprazole (schizophrenia and mania: 30 mg) obtained approvals for psychosis that may limit adverse events but, at the same time, limit benefits. |
2006-02-28 |
2023-08-12 |
Not clear |
| Suzana Uzun, Oliver Kozumplik, Ninoslav Mimica, Vera Folnegović-Smal. The patient with schizophrenia taking aripiprazole: case report. Psychiatria Danubina. vol 17. issue 3-4. 2006-02-15. PMID:16392433. |
the patient with schizophrenia taking aripiprazole: case report. |
2006-02-15 |
2023-08-12 |
Not clear |